Maintenance therapy in multiple myeloma: Two is not always better than one

摘要

In multiple myeloma (MM) long-term therapy aims to control disease and delay progression for as long as possible. In this issue Jenner et al. failed to demonstrate a benefit of maintenance with lenalidomide plus vorinostat compared with lenalidomide in both transplant eligible (TE) and ineligible (NTE) patients enrolled in the Myeloma XI trial. Commentary on: Jenner et al. The addition of vorinostat to lenalidomide maintenance for newly diagnosed multiple myeloma patients of all ages: results from Myeloma XI, a multicentre, open-label, randomised, phase III trial.